Form 4: CARGO Therapeutics Director Sells Options Post-Merger

CARGO Therapeutics Director Jane Henderson disposed of 25,000 stock options following the company's acquisition by Concentra Biosciences for $4.379 cash and one CVR per share.

Summary

• CARGO Therapeutics, Inc. (CRGX) was acquired by Concentra Biosciences, LLC, with Concentra Merger Sub VII, Inc. completing a tender offer for all outstanding shares.
• The tender offer price was $4.379 per share in cash, plus one non-transferable contractual contingent value right (CVR) per share.
• Following the tender offer, Merger Sub merged with and into CARGO Therapeutics, Inc., making CARGO a wholly-owned subsidiary of Concentra Biosciences.
• Director Jane Henderson disposed of 25,000 stock options with an exercise price of $4.35 per share on August 19, 2025.
• As a result of the merger, these options became fully vested and exercisable immediately prior to the merger's effective time.
• Unexercised options were canceled and converted into a cash payment equal to the excess of the cash offer price ($4.379) over the option exercise price ($4.35), multiplied by the number of underlying shares, plus one CVR per underlying share.
• For Jane Henderson's 25,000 options, this resulted in a cash payment of $725.00 (25,000 shares * ($4.379 $4.35)) and 25,000 CVRs.
• Options with an exercise price equal to or greater than the cash amount were canceled for no consideration.

Sentiment

Score: 6

Explanation: The filing reports a standard insider transaction following a completed merger. The disposition of options and receipt of cash and CVRs is a neutral to slightly positive event for the option holder, as it monetizes their equity interest in the acquired company. It reflects the successful completion of a pre-announced corporate action.

Positives

• Outstanding stock options, including those held by Director Jane Henderson, became fully vested and exercisable immediately prior to the merger, providing liquidity.
• Option holders received a cash payment for in-the-money options, providing immediate value.
• The inclusion of Contingent Value Rights (CVRs) offers potential future upside for option holders and shareholders based on future milestones.

Negatives

• Options with an exercise price equal to or greater than the cash offer price were canceled for no consideration, meaning some option holders received no value.
• The cash component received by Jane Henderson for her options was minimal ($0.029 per share), indicating the options were only slightly in-the-money relative to the cash offer.

Future Outlook

The filing primarily reports a completed transaction and the subsequent disposition of insider stock options. The future outlook for former CARGO Therapeutics shareholders and option holders now depends on the performance of the Contingent Value Rights (CVRs), which represent potential future payments based on specific milestones.

Industry Context

This transaction represents a common occurrence in the biotechnology and pharmaceutical sectors, where smaller companies with promising pipelines are acquired by larger entities. The use of Contingent Value Rights (CVRs) is a frequent mechanism in such mergers, particularly when there is significant value tied to future clinical trial outcomes, regulatory approvals, or commercial milestones that are not yet fully realized or certain. This structure allows the acquiring company to mitigate risk while providing potential upside to the acquired company's shareholders.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in this acquisition aligns with common practices in biotech M&A, where such instruments are employed to bridge valuation gaps and share future risks/rewards, especially for assets in development stages.
• While the specific cash premium over the option exercise price for Jane Henderson's options was modest ($0.029 per share), the overall deal structure, including CVRs, is a standard approach for valuing and acquiring biotech companies with pipeline assets.
• Comparable transactions in the biotech space often feature similar structures, such as Bristol Myers Squibb's acquisition of Celgene, which included CVRs tied to regulatory approvals for specific drugs, or Gilead Sciences' acquisition of Forty Seven, which also involved contingent payments.

Stakeholder Impact

• Shareholders of CARGO Therapeutics received a cash payment and CVRs for their shares, providing liquidity and potential future value.
• Option holders, like Director Jane Henderson, had their options monetized into cash and CVRs, or canceled if out-of-the-money, providing a defined outcome for their equity incentives.
• Employees of CARGO Therapeutics are now part of Concentra Biosciences, LLC, following the company becoming a wholly-owned subsidiary.

Next Steps

• Future payments related to the Contingent Value Rights (CVRs) will be contingent upon the achievement of specific milestones as outlined in the CVR Agreement.

Key Dates

Keywords

CARGO Therapeutics, CRGX, Concentra Biosciences, Merger, Acquisition, Tender Offer, Stock Option, Form 4, Insider Transaction, Contingent Value Right, CVR